Detection, Treatment, and Monitoring of Microbiome-Induced Metabolic Dysfunction
AssigneeMcPharma Biotech Inc.
InventorsDerek McLaren, Earl McLaren
Life of this patent
Estimating the term…
Abstract
Individuals consuming a prebiotic and who displayed improvements in blood glucose and/or insulin levels also displayed a decrease in the levels of the non-butyrate-producing Firmicutes genus of bacteria Sporacetigenium. Increasing levels of butyrate-producing Firmicutes genera were not consistently correlated with improvements in metabolism in response to prebiotic consumption. In the general population, Sporacetigenium levels are positively correlated with insulin levels.
Claims31
A method for determining efficacy of a microbiome modulating treatment for high blood glucose or high blood insulin levels in an individual at risk of developing type 2 diabetes or who has developed type 2 diabetes or who has type 2 diabetes, said method comprising:
- detecting Sporacetigenium levels in a first gut microbiome sample from the individual at a first time point;
- determining a first measurement of a type 2 diabetes related parameter of the individual at the first time point;
- administering to the individual an effective amount of a gut microbiome modulating treatment on a dosage regimen or schedule for a suitable period of time;
- following the suitable period of time, obtaining a second gut microbiome sample from the individual;
- detecting Sporacetigenium levels in the second sample;
- determining a second measurement of the type 2 diabetes related parameter of the individual at the second time point;
- comparing Sporacetigenium levels in the second gut microbiome sample to Sporacetigenium levels in the first gut microbiome sample, and
- comparing the first measurement of the type 2 diabetes related parameter and the second measurement of the type 2 diabetes related parameter, wherein if the Sporacetigenium levels in the second sample are lower than Sporacetigenium levels in the first sample and the second type 2 diabetes related parameter is lower than the first type 2 diabetes related parameter, continuing the dosage regimen for the individual.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for determining efficacy of a microbiome modulating treatment for high blood glucose or high blood insulin levels in an individual at risk of developing or who has developed or who has type 2 diabetes, said method comprising:
- detecting Sporacetigenium levels in a first gut microbiome sample from the individual at a first time point;
- administering to the individual a microbiome modulating treatment on a dosage regimen for a suitable period of time;
- following the suitable period of time, obtaining a second gut microbiome sample from the individual;
- detecting Sporacetigenium levels in the second sample;
- and
- comparing Sporacetigenium levels in the second gut microbiome sample to Sporacetigenium levels in the first gut microbiome sample,
- wherein if the Sporacetigenium levels in the second sample are lower than Sporacetigenium levels in the first sample, continuing the dosage regimen for the individual.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for monitoring efficacy of a gut microbiome modulating treatment for high blood glucose or high blood insulin levels in an individual being administered said microbiome modulating treatment, said method comprising:
- detecting Sporacetigenium levels in a first gut microbiome sample from the individual at a first time point;
- following a suitable period of time, obtaining a second gut microbiome sample from the individual;
- detecting Sporacetigenium levels in the second sample;
- and
- comparing Sporacetigenium levels in the second gut microbiome sample to Sporacetigenium levels in the first gut microbiome sample,
- wherein if the Sporacetigenium levels in the second sample are lower than Sporacetigenium levels in the first sample, the microbiome modulating treatment is effective.
A method for determining efficacy of a gut microbiome modulating treatment for high blood glucose or high blood insulin levels in an individual being administered said microbiome modulating treatment, said method comprising:
- detecting Sporacetigenium levels in a first gut microbiome sample from the individual at a first time point;
- determining a first measurement of a type 2 diabetes related parameter of the individual at the first time point;
- following a suitable period of time, obtaining a second gut microbiome sample from the individual;
- detecting Sporacetigenium levels in the second sample;
- determining a second measurement of the type 2 diabetes related parameter of the individual at the second time point;
- comparing Sporacetigenium levels in the second gut microbiome sample to Sporacetigenium levels in the first gut microbiome sample, and
- comparing the first measurement of the type 2 diabetes related parameter and the second measurement of the type 2 diabetes related parameter,
- wherein if the Sporacetigenium levels in the second sample are lower than Sporacetigenium levels in the first sample and the second measurement of the type 2 diabetes related parameter is lower than the first measurement of the type 2 diabetes related parameter, the gut microbiome modulating treatment is effective.
Dependencies are inferred from the claim text.